Business Wire

NY-CITIGROUP

13.9.2022 20:03:03 CEST | Business Wire | Press release

Share
Citi Private Bank Finds Family Offices’ Priorities Transcend Preserving the Value of Financial Assets and include Fostering Family Unity and Continuity

Citi Private Bank’s Family Office Group today released the results of its 2022 Family Office Survey, capturing the thinking and behaviors of some of the most diverse family offices and ultra-high net worth investors globally. At a time of increasingly broad financial and geopolitical challenges, the report outlines areas of opportunities for potential growth in the year ahead.

Seven predominant themes emerged from the survey: 1) concerns go beyond financial assets, 2) portfolio values declined overall year to date, 3) outlook is positive despite the economic and geopolitical uncertainty, 4) direct investing remains a priority, 5) professionalization of the investment function in family offices continues, 6) readiness to manage family unity and continuity will be key for long-term success, and 7) allocations to sustainable and ESG investments have room to grow.

“Each of our family office clients has a unique need and perspective that helps inform how we can support progress towards their financial goals for generations to come,” says Ida Liu, Global Head of Citi Private Bank. “There is a growing awareness of the dual necessity to prepare wealth for families and families for wealth. And as a trusted partner, Citi Private Bank can help them do that.”

While the top three current economic concerns include inflation, fears of a recession and geopolitical uncertainty, family office executives expressed strong interest in preparing for the future. This includes preserving the value of the family’s assets and preparing the next generation to transition into leadership roles as responsible wealth owners. In fact, leadership successions at the family, family office or trustee levels are among the key transitions that a majority of respondents are expecting to face in the next five years.

“We are thrilled to share this year’s survey highlights, reflecting the urgent need for family offices to plan today for a successful future,” says Hannes Hofmann, the new Global Head of the Family Office Group at Citi Private Bank. “I look forward to working with some of the world’s most diverse and sophisticated family offices.”

Despite the concerns and perhaps a reflection of their sentiment that the market may have bottomed out, there is a high degree of optimism for portfolio returns over the next twelve months, with 80% of the family offices expecting portfolio gains and 62% expecting a 5% or higher increase in portfolio value. As far as asset allocation, public equity represents the lion’s share at 23%, but the attractiveness of real estate and private equity remains, representing 35% of asset allocations combined (20% and 15% respectively).

The 2022 Family Office Survey also found that direct investing remains a primary focus for family offices, with about a third of them allocating between 10% and 20% of their portfolio, while another third allocate more than 30%. Direct investments are split almost evenly between real estate (37%) and operating businesses (33%).

“We were excited to have doubled the number of questions this year to gain more valuable insight into the broad challenges family offices are facing and further understand where they want to go,” says Alexandre Monnier, Global Head of Family Office Services & Network. “In this survey we tried to capture where but also how family offices are investing, such as whether they rely on an investment committee or a board. This information helps further inform our clients on steps their peers are taking to address their needs and meet their goals.”

This year’s survey also showed that the opportunity to translate curiosity about sustainable or ESG investments into action remains significant, as 60% of family offices still have not considered aligning some of their portfolio with these themes or are unsure how they align. Co- or direct investment opportunities, private markets more broadly, and innovative strategies and partnerships demonstrate the greatest potential for ESG-related investments.

This year’s survey was initiated during Citi Private Bank’s seventh annual Family Office Leadership Program held in-person in June 2022 for the first time since the onset of the Covid-19 pandemic. The survey was subsequently released to Citi Private Bank’s global family office clients for input. The survey included over 30 questions aimed at gauging investment sentiment and portfolio actions of clients in the wake of macroeconomic headwinds and market volatility in early 2022. It drew responses from nearly 200 participants, of which 126 were completed and considered for this report.

About Citi Private Bank:
Citi Private Bank is dedicated to serving worldly and wealthy individuals and families, providing customized private banking across borders. With around $500 billion in total client business, the franchise serves clients across 50 cities in over 100 countries. Citi Private Bank helps clients grow and preserve wealth, finance assets, make cash work harder, safeguard assets, preserve legacies, and serve family and family business needs. The firm offers clients products and services covering capital markets, managed investments, portfolio management, trust and estate planning, investment finance, banking and aircraft finance, art advisory and finance, and sports finance.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006034/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye